Clinical trials: Biochemically Recurrent Prostate Cancer
Recurrent Prostate Cancer After Surgery
This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned.
There is significant, proven use of radiation for recurrent prostate cancer after surgical resection. This treatment typically is delivered over seven and a half weeks of daily treatments, presenting a burden to patients and the…
- Trial name
- DASBRT-RPC (NCT05946824)
- Testing
- Daily-adaptive Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study
This trial performs user testing of a mobile-friendly patient history collection and genetic education tool to improve healthcare providers' understanding of prostate cancer genetic testing.
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
- Trial name
- NCT04447703
- Testing
- Interview, Internet Based Intervention, Survey Administration
- Where
- 5 sites in United States
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Prostate Cancer
PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer
This Phase 1 trial will evaluate the safety and tolerability of PSA-Activated PSA-PAH1 in subjects who have shown biochemical failure and have either completed at least one primary radiation therapy for prostate cancer and have…
- Trial name
- NCT00379561
- Testing
- PSA-Activated PSA-PAH1
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sophiris Bio Corp
Prostate Cancer
Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy
The primary objective of this study is to evaluate the effect of erlotinib on the PSA response rate in patients with non-metastatic prostate cancer and a rising PSA on androgen deprivation therapy.
- Trial name
- NCT00148772
- Testing
- Erlotinib (Tarceva)
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Endeavor Health